Metabolic Engineering of E. coli for GAG Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing glycosaminoglycans (GAGs) face challenges in achieving high quality and quantity for therapeutic use, particularly due to contamination risks from animal sources and the need for size reduction of GAGs produced by metabolic engineering, which reduces product homogeneity.
Innovation Solution
A process involving genetically modified bacterial cells, specifically Escherichia coli, that express genes for enzymes involved in GAG synthesis from an exogenous beta-galactoside precursor, allowing for the production of chondroitin and heparosan with reduced polydispersity and sizes suitable for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GAGs are extracted from animal tissues, then GAGs can be obtained for therapeutic use, but contamination risks (virus or prion) increase
Solution Approach 1:
The patent uses bacterial cells as an intermediary production system. Instead of directly extracting GAGs from animal tissues (which carries contamination risks), the invention introduces bacterial cells engineered with specific genes (glcA-T, kfoC, kfiD, wbpP) that enable them to synthesize GAGs from a beta-galactoside precursor. The bacteria act as a safe intermediary that produces therapeutic-quality GAGs without the virus or prion contamination risks associated with animal tissue extraction.
2Productivity
If GAGs are produced by metabolic engineering in bacteria, then production quantity increases, but product size is too large requiring depolymerization
Solution Approach 1:
The patent changes the substrate parameter by using a beta-galactoside precursor instead of the natural bacterial acceptor. This parameter change in the substrate leads to controlled polymerization that produces GAGs of appropriate size (14-20 kDa) directly, eliminating the need for subsequent depolymerization steps and maintaining product homogeneity while achieving high production quantities.
3Length of moving object
If depolymerization is performed on produced GAGs, then appropriate size is achieved, but product homogeneity decreases
Solution Approach 1:
The patent applies preliminary action by engineering the bacterial synthesis system to produce GAGs of the correct size (14-20 kDa) directly during the production phase. By using the beta-galactoside precursor and specific gene组合 (glcA-T, kfoC, kfiD, wbpP), the GAGs are synthesized at the appropriate molecular weight from the start, eliminating the need for post-production depolymerization and thereby preserving product homogeneity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the production of GAGs with improved homogeneity and size, reducing the need for depolymerization and minimizing contamination risks, while also being economically viable by using a low-cost exogenous precursor.
Implementation Method 1
The cell is genetically modified to express the genes encoding the enzymes suitable for the synthesis of GAGs from a precursor exogenous to the cell
Data Source
Figure 1~2
Figure 3~4
Figure 5A~5B
AI summary
The present invention relates to a method for in vivo production of glycosaminoglycans (GAG), by metabolic engineering in a genetically modified cell. In a method according to the invention, said cell is genetically modified in order to express the genes coding for the enzymes that are suitable for synthesising GAG from an exogenous precursor, preferably internalised by the cell. According to one specific feature, the present invention relates to a method for producing chondroitin or heparosan in a genetically modified bacterial cell, from an exogenous beta-galactoside precursor, preferably internalised by the cell. According to another specific feature, the present invention relates to the use of an Escherichia coli cell comprising at least the genes glcA-T, kfoC, kfiD and wbpP for the production of chondroitin. According to yet another specific feature, the present invention relates to the use of an Escherichia coli cell comprising at least the genes glcA-T, kfiA, kfiB, kfiC and kfiD for the production of heparosan. The present invention also relates to the use of the obtained glycosaminoglycans by implementing a method according to the invention in order to prepare a drug, a food composition or a cosmetic product.